Research programme: neoantigen-based T cell therapeutics - Neon Therapeutics

Drug Profile

Research programme: neoantigen-based T cell therapeutics - Neon Therapeutics

Latest Information Update: 02 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Neon Therapeutics
  • Class CAR-T cell therapies
  • Mechanism of Action Immunostimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 23 Feb 2016 Neon Therapeutics enter into research collaboration with Netherlands Cancer Institute
  • 17 Feb 2016 Neon Therapeutics in-licenses Peptide-MHC assay technology from Sanquin Blood Supply Foundation
  • 09 Dec 2015 Neon Therapeutics in-licenses neoantigen technology from the Broad Institute, Dana-Farber Cancer Institute and Massachusetts General Hospital
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top